Date | Time | Source | Announcement |
---|---|---|---|
13 Jul 2001 | 07:07 AM | Corporate Action | |
13 Jul 2001 | 07:00 AM | Proposed Placing & Open Offer | |
13 Jul 2001 | 07:00 AM | Preliminary Results | |
29 Jun 2001 | 04:43 PM | Statement re Suspension | |
20 Jun 2001 | 07:00 AM | Additional Funding | |
25 Apr 2001 | 10:31 AM | Additional Funding | |
27 Mar 2001 | 07:00 AM | Funding to Support Expansion | |
31 Oct 2000 | 07:00 AM | Second Interim Results 2000 | |
12 Jul 2000 | 02:24 PM | Interim Statement | |
19 Apr 2000 | 05:10 PM | Result of Open Offer | |
18 Apr 2000 | 05:48 PM | Result of EGM | |
18 Apr 2000 | 11:05 AM | Result of EGM | |
27 Mar 2000 | 07:01 AM | Restoration of Trading on AIM | |
24 Mar 2000 | 04:26 PM | Statement re Restoration of Dealing | |
24 Mar 2000 | 08:47 AM | Entitlement Details | |
24 Mar 2000 | 08:46 AM | Proposed Acquisition and Placing and Open Offer | |
17 Feb 2000 | 01:56 PM | Statement re Suspension of Trading | |
18 Jan 2000 | 03:55 PM | Statement re Share Price Movement | |
26 Nov 1999 | 02:31 PM | Insinger Townsley Appointed as Nominated Broker |
mmuPharma PLC is an AIM listed (LSE:IMM) evolving speciality pharma company headquartered in London with its research R&D team, ImmuPharma Biotech, based in France
IMM research strategy is based on two strategic axes: research based on external collaboration aimed at discovering new active ingredients, which has led to the development of our most advanced project in terms of clinical development: P140 an active peptide against the auto-immune disease, Lupus SLE and internal research based on the use of molecular programming technologies, which has notably led to the development of the BioAMB and BioCIN projects.